4.05
-0.04(-0.98%)
Currency In USD
| Previous Close | 4.09 |
| Open | 4.07 |
| Day High | 4.11 |
| Day Low | 3.96 |
| 52-Week High | 6.26 |
| 52-Week Low | 0.64 |
| Volume | 30,017 |
| Average Volume | 107,925 |
| Market Cap | 18.43M |
| PE | -3.4 |
| EPS | -1.19 |
| Moving Average 50 Days | 4.25 |
| Moving Average 200 Days | 3.1 |
| Change | -0.04 |
If you invested $1000 in Lixte Biotechnology Holdings, Inc. (LIXT) 10 years ago, it would be worth $225 as of December 25, 2025 at a share price of $4.05. Whereas If you bought $1000 worth of Lixte Biotechnology Holdings, Inc. (LIXT) shares 5 years ago, it would be worth $116.71 as of December 25, 2025 at a share price of $4.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
GlobeNewswire Inc.
Dec 23, 2025 1:00 PM GMT
--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a bio
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
GlobeNewswire Inc.
Dec 18, 2025 2:00 PM GMT
BOCA RATON, FLA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that it has entered into definitive agreements in a regi
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
GlobeNewswire Inc.
Nov 25, 2025 1:30 PM GMT
Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdin